In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

Keyphrases

• Pharmacodynamic Interactions 100%
• Gram-negative Bacteria 100%
• Gram-positive 100%
• Glycylcycline 100%
• Klebsiella Pneumoniae (K. pneumoniae) 75%
• Bacteriostatic 75%
• Area under the Concentration-time Curve 50%
• Cmax 50%
• S. Pneumoniae 50%
• Maximal Effect 50%
• Dosing Schedule 50%
• Escherichia Coli ATCC 25922 50%
• Escherichia Coli 25%
• Dose Effect 25%
• Pharmacokinetic Study 25%
• Dose Rate 25%
• Pharmacodynamics 25%
• Microorganisms 25%
• Staphylococcus Aureus 25%
• Pharmacokinetic Parameters 25%
• Elimination Half-life 25%
• Serum Protein Binding 25%
• In Vivo Efficacy 25%
• Drug Combination 25%
• Streptococcus Pneumoniae 25%
• Maximum Permissible Concentration 25%
• Effective Dose 25%
• Twice-daily Dosing 25%
• Dose Finding 25%
• Tetracycline 25%
• Unbound Drug 25%
• Bacteriostatic Activity 25%
• Murine Thigh Infection Model 25%
• Certain Factor 25%
• Rational Design 25%
• Neutropenic Mouse 25%
• Dose-response Model 25%
• Tetracycline Resistant Bacteria 25%

Immunology and Microbiology

• Escherichia coli 100%
• Minimum Inhibitory Concentration 100%
• Gram-Negative Bacteria 100%
• Pharmacodynamics 100%
• Pneumococcus 100%
• Pharmacokinetics 66%
• Body Weight 33%
• Staphylococcus Aureus 33%
• Klebsiella pneumoniae 33%
• Dose Response 33%
• Elimination Half-Life 33%
• Plasma Protein Binding 33%
• Microorganism 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacodynamics 100%
• Gram Negative Bacterium 100%
• Glycylcycline Derivative 100%
• Infection 50%
• Escherichia coli 50%
• Tetracycline 50%
• Klebsiella pneumoniae 25%
• Elimination 25%
• Pharmacokinetic Parameter 25%
• Plasma Protein Binding 25%
• Combination Drug 25%
• Streptococcus 25%
• Staphylococcal Pneumonia 25%
• Dosing Studies 25%
• Escherichia Coli Pneumonia 25%
• Pharmacodynamic Parameter 25%
• Pamicogrel 25%
• Pharmacokinetics 25%
• Microorganism 25%